Stop parsing PDFs. Get the API. Request Access

AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Fresenius Medical Care AG & Co. KGaA

Investor Presentation • Jan 14, 2008

165_ip_2008-01-14_ef3bf2bf-c0a0-40a4-8128-10dcb20c47ab.pdf

Investor Presentation

Open in Viewer

Opens in native device viewer

Fresenius Medical Care

The World's Leading Renal Therapy Company

Dresdner Kleinwort German Investment Seminar

New York, January 14, 2008

Safe Harbor Statement

This presentation includes certain forward-looking statements. Actual results could differ materially from those included in the forward-looking statements due to various risk factors and uncertainties, including changes in business, economic competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings and the availability of financing. These and other risks and uncertainties are detailed in the Company's reports filed with the Securities and Exchange Commission and the German Exchange Commission "Deutsche Börse".

1. Business Update

2. Financials and Outlook

3. Midterm Strategy

4. Attachments

Global Operating Network and Production

* including clinics where FME has an interest of at least 10%

Continued Strong Momentum

(
lu
d
ing
im
i
in
)
-t
te
2
0
0
6
ex
c
o
ne
e
ms
R
e
e
n
e
v
u		 \$
1
5
1
7
m
,		 1
6
%
+
N
i
t		 \$
5
2
0		 3
5
%
e
n
c
o
m
e		 m +
E
i
h
a
r
n
n
g
s
p
e
r
s
a
r
e		 \$
1
6
7		 3
4
%
+
  • X Continued strong performance across all segments and regions
  • X Continued high earnings momentum

Clearly on Track to Achieve the Upper End of Guidance

9M 2007 – Strong Revenue Growth

Total Revenue Increased 16% to \$ 7,151 m *

Dialysis Services - Global

Strong Overall Revenue Growth

\$
i
i
l
l
i
n
m
o
n
s		 9
M
2
0
0
6		 9
M
2
0
0
7		 G
h
t
r
o
w		 c
c
1)
N
h
A
i
t
o
r
m
e
r
c
a		 3
9
9
5
,		 4
4
7
6
,		 1
3
%
I
i
l
t
t
n
e
r
n
a
o
n
a		 6
6
9		 8
8
0		 3
2
%		 2
4
%
1)
T
l
t
o
a		 4
6
2
8
,		 5
3
5
7
,		 1
6
%		 1
5
%

1) Q3 2006 revenue adjusted for sale of perfusion business in the amount of US\$ 27 m

cc = constant currency

Dialysis Products - Global

Continued Excellent Growth

\$
i
i
l
l
i
n
m
o
n
s		 9
M
2
0
0
6		 9
M
2
0
0
7		 G
h
t
r
o
w		 c
c
T
l
t
o
a
r
e
v
e
n
u
e
(
i
l.
I
l
R
)
t
n
c
n
e
r
n
a
e
v
e
n
u
e		 1
9
8
8
,		 2
3
6
0
,		 1
9
%		 1
4
%
E
l
t
x
e
r
n
a
r
e
v
e
n
u
e		 1
1
9
5
,		 1
7
9
4
,		 1
8
%		 1
3
%
N
h
A
i
t
o
r
m
e
r
c
a		 4
0
8		 4
8
1		 1
8
%		 1
8
%
I
i
l
t
t
n
e
r
n
a
o
n
a		 1
1
1
1
,		 1
3
1
3
,		 1
8
%		 1
1
%

Highlights - Global

* Excluding one-time items. A reconciliation to the most directly comparable US-GAAP financial measure is provided in the attachment.

Highlights – Global: Dialysis Products

X Strong growth in products well above market of 18% X PhosLo sales fully in line with expectations

  • Europe
  • X Strong growth in products above market at 17%, y-o-y (8%cc)

being up +79%, y-o-y

X 5008 HD machine unit sales up 135%, y-o-y

  • X Strong product sales growth of 14%cc
  • X Organic revenue growth in China Q3 of 46%cc and Nine Months of 31%cc, y-o-y

Highlights – Global: Dialysis Services

  • X FDA Advisory Panel's decision supports Anemia Management Practices
  • X Active dialogue with U.S. legislators on medically appropriate care for ESRD patients

  • X Strong Revenue/treatment despite EPO discussion

  • X Service Growth in Eastern Europe of 18%cc, ytd

  • X Increase in revenue per treatment of 4%
  • X Online HDF reimbursement recognized in Spain

X Strong treatment growth in Q3 of 119% (14% excl. Jiate Excelsior)

Financials Q3 and Outlook

Profit & Loss1)

\$
i
i
l
l
i
n
m
o
n
s		 M
9
2
0
0
6		 9
M
2
0
0
7
*
N
t
e
r
e
e
n
e
v
u		 6
1
4
7
,		 1
5
1
7
,		 1
6
%
+
O
i
i
(
E
B
I
T
)
t
p
e
r
a
n
g
n
c
o
m
e		 9
3
6		 1
1
5
2
,		 2
3
%
+
E
B
I
T
i
i
%
m
a
r
g
n
n		 1
2
5		 1
6.
1
I
t
t
t
n
e
r
e
s
e
p
e
n
s
e,
n
e
x		 2
4
1		 2
8
1
I
b
f
i
t
n
c
o
m
e
e
o
r
e
n
c
o
m
e
a
x		 6
9
5		 8
1
7		 2
%
5
+
I
t
n
c
o
m
e
a
x
e
x
p
e
n
s
e		 2
8
0		 3
3
1
T
t
a
r
a
e
x		 4
0
%		 3
8
%
M
i
i
I
t
t
t
n
o
r
y
n
e
r
e
s		 1
0		 2
0
N
i
t
e
n
c
o
m
e		 4
0
5		 5
2
0		 2
8
%
+

* 14% growth at constant currency, 7% organic growth

1) Excluding one-time items in 2006

Cash Flow1)

\$
i
i
l
l
i
n
m
o
n
s		 9
M
2
0
0
6		 9
2
0
0
7
m
1)
N
h
i
d
d
b
i
i
i
i
t
t
t
t
e
c
a
s
p
r
o
e
o
p
e
r
a
n
g
a
c
e
s
v
y
v		 6
6
3		 8
9
0
f r
1
2.
4
%
o
ev
en
ue		 3
4
%
+
C
(
)
i
l
d
i
t
t
t
a
p
a
e
x
p
e
n
u
r
e
s
n
e		 (
)
2
3
7		 (
)
3
6
4
C
F
h
F
l
r
e
e
a
s
o
w		 3
9
0		 5
2
6		 3
%
5
+
A
i
i
i
t
c
q
s
o
n
s
u		 (
)
4
4		 (
)
1
1
0
F
C
h
F
l
f
i
i
i
t
t
r
e
e
a
s
o
a
e
r
a
c
q
s
o
n
s
w
u		 3
4
6		 4
1
6

1) Excluding one-time effects in 2006

De-leveraging ahead of schedule

* Including non-cash charges and excluding restructuring costs, in-process R&D and gain from the sale of dialysis clinics.

Continued Strong Growth in Earnings per Share

Earnings per Share

* CAGR = Compound Annual Growth Rate

\$
i
i
l
l
i
n
m
o
n
s		 G
i
d
2
0
0
7
a
n
c
e
u
N
R
t
e
e
v
e
n
u
e
s		 9
5
0
0
>
N
I
t
e
n
c
o
m
e		 5
5
6
8
7
0
-
L
i
t
e
e
r
a
g
e
r
a
o
v
(
/
)
D
b
E
B
I
T
D
A
t
e		 3
0
<
C
E
d
i
i
i
t
a
p
a
n
a
c
q
s
o
n
s
x
u		 6
5
0
~

X Clearly on Track for the Upper End of Net Income Guidance

X Leverage Ratio Target already Achieved after Nine Months

Fresenius Medical Care

Midterm Strategy

World Leader in Products & Services

\$9 billion Products Market

\$46 billion Services Market

* Number of Patients Treated Q3 2007

Growth in Number of Dialysis Patients – Worldwide

  • •Renal failure persists as a chronic worldwide epidemic
  • •Dialysis is the primary treatment modality for renal failure on a global scale
  • • Exponential growth trend continues on a global scale as incidence (new cases) and patient survival improve.

Sustainable Patient Growth of 5-6% p.a.

~ 2 Million Patients Worldwide by 2010

15%

N
h
A
i
t
o
r
m
e
r
c
a		 3
%		 i
L
t
a
i
A
m
e
r		 n
c
a
E
r
o
p
e
u		 4
5
%
-		 1
2
%		 E
M
E
A
2
9
%
i
i
L
A
t
a
n
m
e
r
c
a		 1
0
%		 /
A
i
s
a
i
f
i
P
a
c
c
A
i
P
i
f
i
s
a
a
c
c
-		 6
%		 3
5
%		 N
h
A
i
t
o
r
m
e
r
c
a
i
W
l
d
d
o
r
w
e		 5
6
%
-		 2
4
%
J
a
p
a
n

Market Opportunity

Peritoneal Dialysis 9 Hemodialysis 9 Innovative Therapy Options Strong organic growth 9 Superior patient care 9 Cost leader 9USA – RCG 9Eastern Europe Asia Pacific (non Japan) EPO 9Phosphate Binders 9 Vitamin DIronDialysis ProductsDialysis ProductsDialysis Drugs Dialysis Services AdditionaIIn-patient Dialysis ServicesPD HD Acute Acute Road 1Organic Growth Road 2Acquisitions Road 3Horizontal Expansions Road 4Home Dialysis \$67 billion Dialysis Market 2010

Integrated Patient Care Model – Clinic Centric

Cost of Care for ESRD Patients

ESRD Demo Project – Member Total Annual Cost \$72,000 (2006 Financial Data)

  • Dialysis (38.5%)
  • Hospital (31.3%)
  • Hospital OutPatient (5.8%)
  • Nephrology (3.8%)
  • Surgery (4.3%)
  • Specialty (4.5%)
  • Lab/Path/Rad (3.5%)
  • Home Health/DME/Ambulance/Other (8.2%)

Summary - Growth Drivers

Renal Pharma

Expansion of Clinic Network Revenue Growth per Year

Reimbursement Based on Quality

Increased Product Market Share

Product & Service Innovation

Global Patient Growth

N
h
A
i
t
o
r
m
e
r
c
a		 6
%
E
u
r
o
p
e		 1
0
%
A
i
P
i
f
i
s
a
a
c
c
-		 1
5
%

2010 Revenue Target

~10-15% per Year

Thank you for your kind attention !

Attachments

Reconciliation of non US-GAAP financial measures to the most directly comparable US-GAAP financial measure

D
b
t
e		 Q
3
2
0
0
7		 F
Y
2
0
0
6		 F
Y
2
0
0
5		 F
Y
2
0
0
4		 F
Y
2
0
0
3
1)
S
ho
bo
ing
(
inc
l.
A
/
R
)
t
te
r
rm
rro
w
s
p
ro
g
ra
m		 7
6		 3
3
1		 1
5
1		 4
1
9		 9
0
S
ho
bo
ing
fro
la
d p
ies
t
te
te
t
r
rm
rro
w
s
m
re
ar
+		 4
6		 5 1
9		 6 3
0
Cu
ion
f
lon
de
b
d c
i
l
lea
b
l
ig
ion
t p
t
te
t a
ta
t
+
rre
n
or
o
g-
rm
n
ap
se
o
a
s		 4
6		 1
6
0		 1
2
6		 2
3
0		 9
0
Cu
Se
ion
f
Tr
Pr
fe
d
i
ies
t p
t
t
t
rre
n
or
o
us
e
rre
cu
r
+		 6
6
5
Lo
de
b
d c
i
l
lea
b
l
ig
ion
les
ion
-te
t a
ta
t
t p
t
ng
rm
n
ap
se
o
a
s,
s c
ur
re
n
or
+		 4,
0
3
2		 3,
8
2
9		 7
0
7		 5
4
5		 1,
1
1
2
Tr
Pr
fe
d
Se
i
ies
(
f c
ion
)
t
t
t o
t p
t
+
us
e
rre
cu
r
ne
ur
re
n
or		 6
4
8		 5
1,
2
4		 1,
1
8
8		 1,
2
7
9		 1,
2
4
2
iva
i
iza
ion
Ac
ts
b
le
t
t
co
un
rec
e
se
cu
r
p
ro
g
ra
m
+		 0 0 0 0 1
5
8
To
l
de
b
ta
t
=		 1
3
5,
5		 9
5,
5
7		 2,
1
9
1		 2,
4
9
7		 2,
2
2
7

All numbers are in \$ millions

E
B
I
T
D
A		 2)
Q
3
2
0
0
7		 2)
F
Y
2
0
0
6
(pr
o f
)
orm
a		 F
Y
2
0
0
5		 F
Y
2
0
0
4		 F
Y
2
0
0
3
La
lve
hs
ing
inc
(
E
B
I
T
)
t
tw
t
t
s
e
m
on
o
p
er
a
om
e		 1,
5
3
3		 1,
3
6
7		 9
3
9		 8
5
2		 7
5
7
La
lve
hs
de
ia
ion
d a
iza
ion
t
tw
t
t
t
t
+
s
e
m
on
p
rec
an
mo
r		 3
4
7		 3
2
6		 2
5
1		 2
3
3		 2
1
6
No
h c
ha
+
n-c
as
rg
es		 3
7		 3
5		 1
4		 1
3		 1
3
(
)
E
B
I
T
D
A
l
ize
d
an
nu
a
=		 1,
9
1
7		 1,
7
2
8		 1,
2
0
4		 1,
0
9
8		 9
8
6

1) A/R securitization program off-balance sheet in 2003 and included in short term borrowings from 2004 onwards 2) Excluding restructuring costs and in-process R&D

Attachment II

Reconciliation of non US-GAAP financial measures to the most directly comparable US-GAAP financial measure

All numbers are in \$ millions

E
l
R
t
x
e
r
n
a
e
v
e
n
u
e		 Q
3
2
0
0
7		 Q
3
2
0
0
6		 h
t
g
row		 cc
In
io
l
du
te
t
t r
rn
a
na
p
ro
c
ev
en
ue		 5
2
4		 4
3
9		 1
9
%
+		 1
1
%
+
In
l re
te
rna
ve
nu
e
-		 (
6
)
5		 (
0
)
5
Ex
l r
te
rn
a
ev
en
ue
=		 4
5
9		 3
8
9		 1
8
%
+		 9
%
+
ica
No
t
h
Am
du
t r
r
er
p
ro
c
ev
en
ue		 2
9
7		 2
6
8		 1
1
%
+
In
l re
te
rna
ve
nu
e
-		 (
1
3
0
)		 (
1
2
)
7
Ex
l r
te
rn
a
ev
en
ue
=		 1
6
7		 1
4
1		 1
8
%
+
T
O
T
A
L
du
t r
p
ro
c
ev
en
ue		 8
2
1		 0
7
5		 1
6
%
+		 1
1
%
+
In
l re
te
rna
ve
nu
e
-		 (
1
9
6
)		 (
1
7
5
)
Ex
te
l r
rn
a
ev
en
ue
=		 6
2
5		 5
3
0		 1
8
%
+		 1
2
%
+
C
(
)
i
l
d
i
t
t
t
a
p
a
e
x
p
e
n
u
r
e
n
e		 9
M
2
0
0
7		 Q
3
2
0
0
7		 Q
3
2
0
0
6		 9
M
2
0
0
6
Pu
ha
f p
lan
d
ip
ty
t a
t
rc
se
o
ro
p
er
p
n
eq
u
m
en
,		 3
8
6		 1
3
4		 1
1
5		 2
8
8
Pr
ds
fro
le
f p
lan
d
ip
ty
t a
t
oc
ee
m
sa
o
ro
p
er
p
n
eq
u
m
en
-
,		 (
2
2
)		 (
1
1
)		 (
2
)		 (
1
5
)
Ca
(
)
i
l e
d
i
ta
tu
t
p
xp
en
re
ne
=		 3
6
4		 1
2
3		 1
1
3		 2
7
3

cc = constant currency

Attachment III

Reconciliation of non US-GAAP financial measures to the most directly comparable US-GAAP financial measure

O
i
f
b
f
i
i
t
t
t
p
e
r
a
n
g
p
e
r
o
r
m
a
n
c
e
e
o
r
e
o
n
e-
m
e
e
m
s		 Q
3
2
0
0
7		 Q
3
2
0
0
6		 h
t
g
row
Op
ing
inc
(
E
B
I
T
)
t
er
a
om
e		 3
9
7		 3
4
9		 1
4
%
Ga
in
fro
d
ive
i
in
t
tu
tru
tu
m
s
re
re
s
c
r
g
+		 0 6
Op
ing
inc
(
E
B
I
T
)
be
fo
im
i
t
t
te
er
a
om
e
re
on
e-
e-
ms		 3
9
7		 3
5
5		 1
2
%
Ne
in
t
co
me		 1
8
1		 1
3
9		 3
0
%
fro
ive
i
in
Lo
d
t
tu
tru
tu
ss
m
s
re
re
s
c
r
g
,		 0 4
fo
Ne
inc
be
im
i
t
t
te
om
e
re
on
e-
e-
ms		 1
8
1		 1
4
3		 2
7
%

All numbers are in \$ millions

P
f
i
&
L
A
t
t
r
o
o
s
s
c
c
o
u
n		 Q
3
2
0
0
6		 On
im
i
t
tem
e-
e
s		 Q
3
2
0
0
6
lu
d
ing
im
i
t
tem
ex
c
on
e-
e
s
Ne
t r
ev
en
ue		 2,
2
3
4		 2,
2
3
4
Op
in
in
(
E
B
I
T
)
t
er
a
g
co
me		 3
4
9		 *
6		 5
5
3
(
)
E
B
I
T-
in
%
m
ar
g		 1
5.
6		 1
5.
9
In
te
t e
t
res
xp
en
se
ne
,		 (
)
1
0
0		 (
)
1
0
0
In
be
fo
in
ta
co
m
e
re
co
m
e
xe
s		 2
4
9		 6 2
5
5
Inc
Ta
om
e
x e
xp
en
se		 (
)
1
0
6		 (
)
2		 (
)
1
0
8
(
)
Ta
%
te
x r
a		 4
2		 4
2
M
ino
i
in
ty
te
t
r
re
s		 (
4
)		 (
4
)
in
Ne
t
co
me		 1
3
9		 4 1
4
3

* Restructuring costs of US\$ 7 m, less gain from divestiture of US\$ 1 m

Attachment IV

Reconciliation of non US-GAAP financial measures to the most directly comparable US-GAAP financial measure

All numbers are in \$ millions

P
f
i
&
L
A
t
t
r
o
o
s
s
c
c
o
u
n		 M
9
2
0
0
6		 On
im
i
t
tem
e-
e
s		 M
9
2
0
0
6
lu
d
ing
im
i
t
tem
ex
c
on
e-
e
s
Ne
t r
ev
en
ue		 6,
1
4
7		 6,
1
4
7
in
in
(
)
Op
t
E
B
I
T
er
a
g
co
me		 9
6
4		 *
(
)
2
8		 9
3
6
E
B
I
T-
in
(
)
%
m
ar
g		 1
5.
7		 1
5.
2
In
te
t e
t
res
xp
en
se
ne
,		 (
2
)
5
5		 **
1
4		 (
2
4
1
)
fo
In
be
in
ta
co
m
e
re
co
m
e
xe
s		 7
0
9		 (
)
1
4		 6
9
5
Inc
Ta
om
e
x e
xp
en
se		 (
)
3
1
4		 3
4		 (
)
2
8
0
Ta
(
%
)
te
x r
a		 4
4
%		 4
0
M
ino
i
in
ty
te
t
r
re
s		 (
1
0
)		 (
1
0
)
Ne
in
t
co
me		 5
3
8		 2
0		 5
4
0
O
i
i
N
h
A
i
t
t
p
e
r
a
n
g
n
c
o
m
e
o
r
m
e
r
c
a		 Q
3
2
0
0
6		 M
9
2
0
0
6
Re
ve
nu
e		 1,
6
1
3		 4,
3
6
7
Op
(
)
ing
inc
E
B
I
T
t
er
a
om
e		 2
5
7		 7
0
4
E
B
I
T
in
(
in
%
f r
)
m
ar
g
o
ev
en
ue		 1
5.
9
%		 1
6.
1
%
On
im
i
t
te
e-
e-
m
s		 6 (
3
0
)
in
(
in
f r
)
fo
im
i
E
B
I
T
%
be
-t
te
m
ar
g
o
ev
en
ue
re
o
ne
e
m
s		 1
6.
3
%		 1
5.
4
%

* US\$ 40 m gain from divestiture, less US\$ 10 m restructuring costs and US\$ 2 m costs for transformation of the legal form of the Company ** Write-off of deferred financing costs

Attachment V

Reconciliation of non US-GAAP financial measures to the most directly comparable US-GAAP financial measure

All numbers are in \$ millions

C
h
F
l
a
s
o
w		 Q
3
2
0
0
7		 9
M
2
0
0
7
Ac
is
i
ion
t
q
s
u		 (
)
2
6		 (
)
1
4
0
Pr
ds
fro
d
ive
i
t
tu
oc
ee
m
s
res		 2 3
0
Ac
is
i
io
f
d
ive
i
t
t o
t
tu
q
ns
ne
s
re
s
u
,		 (
)
2
4		 (
)
1
1
0
C
h
F
l
a
s
o
w		 Q
3
2
0
0
6		 Ta
for
ts
x p
ay
me
n
ior
p
r
y
ea
rs		 C
G
R
is
i
ion
t
ac
q
u		 Q
3
2
0
0
6
i
in
iv
i
ies
Ne
h
de
d
by
t c
t
t
t
as
p
ro
o
p
er
a
g
ac
v		 1
5
3		 9
9		 9 2
6
1
Ca
i
l
Ex
d
i
(
)
ta
tu
t
p
p
en
res
ne		 (
1
1
3
)		 (
1
1
3
)
Ca
Fr
h
F
low
ee
s		 4
0		 9
9		 9 1
4
8
Ac
is
i
ion
d
d
ive
i
t
t
tu
q
s a
n
s
res
u		 (
)
8		 (
)
2		 (
)
1
0
Fr
Ca
h
F
low
f
is
i
io
d
d
ive
i
te
t
t
tu
ee
s
a
r a
cq
u
ns
a
n
s
re
s		 3
2		 9
9		 7 1
3
8
C
h
F
l
a
s
o
w		 9
M
2
0
0
6		 for
Ta
ts
x p
ay
me
n
ior
p
r
y
ea
rs		 C
G
R
is
i
t
ion
ac
q
u		 9
M
2
0
0
6
Ne
h
i
de
d
by
in
iv
i
ies
t c
t
t
t
as
p
ro
v
o
p
er
a
g
ac		 5
4
6		 9
9		 9
9		 6
6
3
Ca
i
l
Ex
d
i
(
)
ta
tu
t
p
p
en
res
ne		 (
2
3
)
7		 (
2
3
)
7
Fr
Ca
h
F
low
ee
s		 1
9
2		 9
9		 9
9		 3
9
0
Ac
is
i
ion
d
d
ive
i
t
t
tu
q
u
s a
n
s
res		 (
)
3,
6
8
2		 3,
6
3
8		 (
)
4
4
Fr
Ca
h
F
low
f
is
i
io
d
d
ive
i
te
t
t
tu
ee
s
a
r a
cq
u
ns
a
n
s
re
s		 (
3,
4
9
0
)		 9
9		 3,
3
7
7		 3
4
6

Contacts

Fresenius Medical Care AG & Co. KGaAInvestor RelationsElse Kröner Str. 161352 Bad Homburg v.d.H.

Oliver Maier

Head of Investor Relations & Corporate Communications Tel.: +49-(0)6172-609-2601 Fax.: +49-(0)6172-609-2301 Mob.: +49-(0)173-6522-712 Mail: [email protected]

North America:

Terry L. Proveaux Tel.: +1-800-948-2538Fax.: +1-615-345-5605Mob.: +1-615-618-2987 bbMail: [email protected]

Ordinary shares

WKN 578 580ISIN DE0005785802SEDOL1 5129074 DE

For your information …

For recent updates, please have a look at our webpage. Navigation around

www.fmc-ag.com

CalendarInvestor Relations > Financial Calendar

Annual Report / Quarterly Filings / SEC Filings / Deutsche Börse Filings ... Investor Relations > Publications

Corporate Governance / Sarbanes-Oxley Act / NYSE declaration ... Investor Relations > Corporate Governance

Financing / Analyst Coverage / Consensus estimates / Share data … Investor Relations > Our share

More from Fresenius Medical Care AG & Co. KGaA

Declaration of Voting Results & Voting Rights Announcements 2026
Jan 16
Share Issue/Capital Change 2026
Jan 12
Transaction in Own Shares 2026
Jan 9
Share Issue/Capital Change 2025
Dec 29
AGM Information 2025
Dec 22
Declaration of Voting Results & Voting Rights Announcements 2025
Dec 15
Declaration of Voting Results & Voting Rights Announcements 2025
Dec 12
Declaration of Voting Results & Voting Rights Announcements 2025
Dec 8
Declaration of Voting Results & Voting Rights Announcements 2025
Dec 3
Transaction in Own Shares 2025
Dec 1
View all filings →

Talk to a Data Expert

Have a question? We'll get back to you promptly.